Gilead Sciences Inc
NASDAQ: GILD
$91.35
+$0.86 (+1.0%)
Closing Price on November 26, 2024
GILD Articles
Gilead Sciences is the first company to cross the finish line for regulatory approval in the fight against the coronavirus.
Published:
Some battered stocks that have not risen back to their highs are attracting some interesting analyst upgrades and new coverage.
Published:
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
24/7 Wall St. has been reviewing many sectors for leadership heading into earnings. One area that can offer some defensive strategies is biotech and pharmaceuticals.
Published:
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United...
Published:
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Gilead Sciences would not be the first company to pile on more debt to make an acquisition, but it is now eating deep into its cash for this acquisition.
Published:
These four high-conviction health care stock ideas from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest of 2020...
Published:
Immunomedics shares more than doubled on Monday after the firm announced that it would be acquired by Gilead Sciences in one of the biggest deals to go down in the health care sector this year.
Published:
Monday's top analyst upgrades and downgrades included Adobe, BP, FedEx, GameStop, Gilead Sciences, Kroger, MGM Resorts, Micron Technology, Nvidia and Tradeweb Markets.
Published:
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
Published:
Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc. (NASDAQ: GILD). This deal is for the discovery and...
Published:
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
Published: